Tiziana Life Sciences is trading at $1.18, up 5.86%, with its September 30 FDA request the clearest company-specific catalyst; the precise cause of the October 1 move is not established. - Shares closed at $1.11 on September 30, up 16.39%, before rising further on October 1. - The request seeks orphan drug designation for intranasal foralumab in multiple system atrophy; it is not a designation or approval. - Foralumab is being evaluated in a Phase 2a trial, and no separate October 1 company announcement was identified.